Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by Checkpoint Capital L.P.

Checkpoint Capital L.P. trimmed its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 250,000 shares of the company’s stock after selling 250,089 shares during the period. Trevi Therapeutics comprises 0.4% of Checkpoint Capital L.P.’s investment portfolio, making the stock its 15th largest position. Checkpoint Capital L.P.’s holdings in Trevi Therapeutics were worth $835,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of TRVI. BNP Paribas Financial Markets raised its stake in shares of Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after acquiring an additional 6,764 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at about $47,000. Hsbc Holdings PLC acquired a new position in shares of Trevi Therapeutics during the second quarter worth $61,000. Intech Investment Management LLC purchased a new stake in Trevi Therapeutics during the 3rd quarter worth $63,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after acquiring an additional 11,450 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at approximately $644,205.26. The trade was a 4.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 17,040 shares of company stock valued at $51,540 in the last three months. 24.37% of the stock is currently owned by corporate insiders.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $2.88 on Monday. Trevi Therapeutics, Inc. has a 12 month low of $1.00 and a 12 month high of $4.00. The stock has a fifty day moving average price of $3.04 and a 200 day moving average price of $2.91. The company has a market cap of $221.37 million, a P/E ratio of -6.55 and a beta of 1.01.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the prior year, the business earned ($0.08) EPS. As a group, research analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on TRVI. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, October 22nd. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Raymond James began coverage on Trevi Therapeutics in a report on Friday, August 30th. They set an “outperform” rating and a $9.00 target price on the stock. B. Riley reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research note on Friday, November 8th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $7.43.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.